Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban (Q43284790)

18 November 2017

title

Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban (English)

1 reference

18 November 2017

1 reference

1 reference

1 reference

1 reference

Juan Pablo Ordovás Baines

1

1 reference

18 November 2017

Eduardo Climent Grana

2

1 reference

18 November 2017

Alejandro Jover Botella

3

1 reference

18 November 2017

Isabel Valero García

4

1 reference

18 November 2017

language of work or name

non-English

0 references

publication date

1 May 2009

1 reference

Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria

18 November 2017

published in

1 reference

18 November 2017

volume

33

1 reference

18 November 2017

issue

3

1 reference

18 November 2017

page(s)

125-133

1 reference

New anticoagulants for treatment of venous thromboembolism.

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

New anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

1 reference

7 January 2021

Venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Latest medical treatment strategies for venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

1 reference

7 January 2021

New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Recent developments in antithrombotic therapy: will sodium warfarin be a drug of the past?

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Beyond heparin and warfarin: the new generation of anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Structure-based design of novel potent nonpeptide thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Advances in the development of thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

What is all that thrombin for?

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

The dynamics of thrombin formation

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Rivaroxaban: an oral direct inhibitor of factor Xa.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Factor Xa or thrombin: is thrombin a better target?

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Direct thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

The ecarin clotting time, a universal method to quantify direct thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2809%2971154-7

7 January 2021

10.1016/S1130-6343(09)71154-7

Identifiers

DOI

1 reference

18 November 2017

1 reference